<DOC>
	<DOCNO>NCT00242554</DOCNO>
	<brief_summary>To assess effect i.v . zoledronic acid 4 mg respect safety tolerability</brief_summary>
	<brief_title>Open-label Phase IV Clinical Trial Evaluate Safety Tolerability Zoledronic Acid Patients With Prostate Cancer Bone Metastases</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Age â‰¥ 18 year Histological confirm diagnosis carcinoma prostate Current previous evidence metastatic disease bone Receiving currently , hormonal therapy ECOG performance status 0 , 1 , 2 Patients abnormal renal function evidence either serum creatinine determination 1.5 x great upper limit normal , calculated creatinine clearance 60 ml/minute less . Corrected serum calcium concentration , adjust serum albumin &lt; 8.0 mg/dl ( 2.00 mmol/L ) . WBC &lt; 3.0x10^9 , ANC &lt; 1500/mm3 , Hb &lt; 8.0 g/dL , platelet &lt; 75 x 10^9/L . Liver function test &gt; 2.5 ULN , serum creatinine &gt; 1.5 ULN . Patients another non malignant disease , could confound evaluation primary endpoint , prevent patient comply protocol . Known hypersensitivity zoledronic acid bisphosphonates compound perform formula . Other protocolrelated inclusion / exclusion criterion may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Bone Metastases</keyword>
	<keyword>Zoledronic acid</keyword>
</DOC>